Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $84,176.45 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,045 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the sale, the chief financial officer owned 105,798 shares in the company, valued at approximately $2,201,656.38. This represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Neurogene Trading Down 1.6%

Shares of NGNE opened at $19.19 on Friday. The stock has a market cap of $297.25 million, a PE ratio of -4.67 and a beta of 1.53. Neurogene Inc. has a 1 year low of $6.88 and a 1 year high of $37.27. The stock has a 50 day simple moving average of $19.19 and a 200-day simple moving average of $21.61.

Hedge Funds Weigh In On Neurogene

A number of institutional investors and hedge funds have recently bought and sold shares of NGNE. BNP Paribas Financial Markets grew its holdings in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Neurogene by 43.6% in the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Neurogene in the fourth quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Neurogene during the 4th quarter worth about $165,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NGNE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Neurogene from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Canaccord Genuity Group began coverage on shares of Neurogene in a research report on Friday, February 27th. They set a “buy” rating for the company. Lifesci Capital initiated coverage on shares of Neurogene in a report on Monday, January 26th. They set an “outperform” rating and a $50.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.